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Association between IL13 Polymorphisms and
Psoriatic Arthritis Is Modified by Smoking
Kristina Callis Duffin1,6, Ingrid C. Freeny2,6, Steven J. Schrodi3, Bob Wong4, Bing-Jian Feng1,
Razieh Soltani-Arabshahi1, Tina Rakkhit5, David E. Goldgar1 and Gerald G. Krueger1
Genetic and environmental factors influence the development of psoriasis (Ps) and psoriatic arthritis (PsA).
Recently, we reported that three IL13 polymorphisms, rs1800925, rs20541, and rs848, on chromosome 5q31
conferred the risk for Ps. IL13 encodes IL-13, a Th2 cytokine, and rs1800925 and rs20541 confer risk of asthma.
Further, smoking may increase the risk of developing Ps. We examined the association between IL13
polymorphisms, smoking, and PsA in two Ps sample sets genotyped for rs1800925, rs20541, and rs848. We found
that the minor alleles (rs1800925*T, rs20541*A, and rs848*A) were significantly associated with protection from
PsA versus controls, and that no association with Ps is seen when the PsA cases are excluded. This effect was
strongest with rs1800925*T (odds ratio (OR) 0.40, Pallelic 0.000067). The prevalence of PsA in cases with the
rs1800925*CT or TT genotype is about half that of those with the CC genotype (15.5 vs 32.1%, P¼ 0.0002).
However, smoking appears to abrogate this effect (CT/TT/non-smoker, prevalence of PsA 13%, OR 0.20,
P¼ 0.0001; CT/TT/smoker, prevalence 38%, OR 0.88, P¼ 0.74, CC/non-smoker, prevalence 42% (reference), CC/
smoker prevalence 47%, OR 1.21, P¼ 0.47). This study suggests that IL13 polymorphisms associate most strongly
with PsA and that smoking may modulate this effect.
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INTRODUCTION
Genetic and environmental factors are known to influence
the development and phenotypic features of psoriasis (Ps) and
psoriatic arthritis (PsA). Twin concordance studies and
familial clustering of Ps are well known and support a strong
genetic component (Brandrup et al., 1982). HLA-Cw*0602,
which lies in the PSORS1 risk locus on chromosome 6, is
believed to confer the greatest risk of Ps of any locus (Nair
et al., 2006). However, this genetic risk factor is also strongly
correlated with environmental factors that augment the Ps
phenotype, including streptococcal pharyngitis, which is
associated with guttate Ps in HLA-Cw0602-positive patients
and Ps induced by trauma (Koebner phenomenon) (Gudjons-
son et al., 2003, 2006; Holm et al., 2005). Recently, a
case–control study in a Chinese population found a several
fold increase in the risks of Ps in patients who smoke or have
stressful life events and carry HLA-Cw6 (Jin et al., 2008).
Tobacco use and other environmental factors such as obesity
have also been shown to be risk factors for the development
of Ps (Setty et al., 2007).
Psoriatic arthritis, which develops in 6–42% of patients with
Ps (Gelfand et al., 2005), is also thought to have a strong and
complex genetic basis. PsA has been associated with
numerous HLA antigens, including HLA-Cw*0602 (Gladman
and Farewell, 2003), HLA-B27, and others, as well as several
outside of the major histocompatibility complex (reviewed by
Duffin et al., 2008). Similar to Ps, certain markers associate
with PsA phenotype: patients who have HLA-Cw*0602 and
HLA-DRB1*07 typically have a less severe course (Ho et al.,
2007); patients with HLA-B27 tend to have spinal manifesta-
tions, whereas carriers of HLA-B38 and HLA-B39 tend to have
more peripheral involvement (Gladman and Farewell, 2003).
More recently, HLA-Cw*0602 has been shown to associate
only with PsA in patients with younger age of onset of Ps (Ho,
2008). It has been speculated that trauma may increase the risk
of developing PsA, perhaps the equivalent of the Koebner
phenomenon in skin (Ryan, 1991; Pattison et al., 2008).
Although familial clustering has been observed in PsA (Moll
andWright, 1973), a recent study of twins in Denmark showed
equivalent rates of monozygotic and dizygotic twin concor-
dance, suggesting that environmental triggers may have a large
role in the development of PsA (Pedersen et al., 2008). Little is
known about gene–environment interaction in PsA.
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In the past 3 years, genome-wide case–control association
studies have identified several new genetic polymorphisms
that confer risk of Ps and PsA. Polymorphisms in IL12B,
IL23R, and IL13 have been shown by our group and others to
confer modest risk of Ps (Capon et al., 2007; Cargill et al.,
2007; Smith et al., 2007; Li et al., 2008; Nair et al., 2008;
Chang et al., 2008). Although it is now apparent that IL12B
and IL23R genes encode cytokines and cytokine receptors
that are important in the pathogenesis of Ps, the functional or
causative roles for these polymorphisms are not known, and
the role of IL13 in Ps is particularly unclear (Duffin and
Krueger, 2008).
IL13, located on chromosome 5q31, encodes the cytokine
IL-13. Four polymorphisms in the IL13/IL4 region, including
rs1800925, located 1 kb 50 of the IL13 coding region, rs20541
(a missense polymorphism in exon 4, Q144R), rs848 (in the
30UTR), and rs11568506 (located in an intron of SLC22A4),
have been shown to associate with Ps in a genome-wide
study and follow-up fine-mapping study of our Utah sample
set (Li et al., 2008; Chang et al., 2008); association of rs20541
and rs848 with Ps was also seen in the Genetics Association
Information Network genome-wide study of Ps (Nair et al.,
2009). IL-13, a Th2 cytokine, is not known to be expressed in
psoriatic skin, but it has been found in the synovial fluid of
patients with PsA (Spadaro et al., 2002). IL-13 has an
important role in Th2-mediated immune disorders such as
asthma and chronic obstructive pulmonary disease (COPD),
and IL13 polymorphisms rs1800925 and rs20541 are
associated with the risk of asthma and COPD (Heinzmann
et al., 2000). There is also increasing evidence that there may
be a gene–environment interaction between IL13 polymorph-
isms and tobacco that affects the clinical features of Th2
disorders. Homozygosity of the minor allele (T) of rs1800925
is associated with increased risk for smokers to develop
diminished FEV1, FEV1/FVC ratio, and COPD when com-
pared with smokers carrying the common C allele (Sadegh-
nejad et al., 2007). Children with the common haplotype of
three IL13 polymorphisms, which include rs1800925 and
rs20541, are more likely to develop asthma if exposed to
smoking by their mothers in utero (Sadeghnejad et al., 2008).
As smoking is considered a risk factor for the development
of Ps, we hypothesized that there may be an association
between the IL13 polymorphisms that confer risk of Ps,
tobacco use, and phenotypic features of Ps. In addition, as
data from our sample set have also shown that certain
characteristics, such as age of onset of PsA, can be influenced
by smoking history (Rakkhit et al., 2007), we specifically
sought to examine the possible interaction between smoking
and IL13 polymorphisms on the development of PsA.
RESULTS
Demographics
Of the 698 Utah cases that had been genotyped and were
eligible for analysis, 181 had PsA, and 447 had cutaneous Ps
only. Seventy cases were excluded on the grounds of having
an equivocal arthritis diagnosis. Of the 447 cases with Ps
only, 334 had Ps X10 years without PsA. Baseline
characteristics of the 334 patients with Ps X10 years and
the 181 PsA patients are shown in Table 1. There was a
marginally significant trend for more females to have PsA,
and for more males to have Ps only (P¼0.048). The mean
age of Ps onset in the Ps group was not statistically different
from the PsA group (22.7±14.4 vs 25.9±14.3). The mean
age of onset of the PsA was 37.5 years, and the mean duration
of PsA was 13.1 years. The prevalence of smoking was 32.1%
in the Ps only group, and 38.9% in the PsA group (P¼ 0.12).
The minor allele of rs1800925 associates with protection from
PsA
Recently, we have shown association of Ps with four
polymorphisms in the IL13/IL4 region: rs1800925 (located
in the 50 promoter region), rs20541 (located within exon 4 of
IL13), rs848 (located in the 30UTR), and rs11568506 (located
in an intron of SLC22A4) (Li et al., 2008; Chang et al., 2008).
Although many other single-nucleotide polymorphisms
(SNPs) in the region associate with Ps, analysis taking into
account linkage disequilibrium showed that rs1800925 and
rs11568506 independently confer risk, and rs11568506 is
only marginally significant. Therefore, we sought to deter-
mine whether a correlation existed between the polymorph-
isms that conferred the most risk (rs1800925) and clinical
features of Ps. We found that PsA was less frequent in cases
with the rs1800925*CT or TT genotype compared with the
CC genotype (15.5 vs 32.1%, P¼ 0.0002, odds ratios
(OR)¼0.38) (Table 2). Other phenotypic features, including
gender, age of onset of Ps, and mean age of onset of PsA,
were not statistically different.
This finding prompted us to further analyze the relation-
ship between PsA and the IL13 polymorphisms. The cases
were divided into three groups: PsA, cutaneous Ps only
(‘‘Ps’’), and cutaneous Ps for X10 years without PsA; allele
and genotype frequencies for rs1800925, rs20541, and rs848
Table 1. Demographics of Utah cases with psoriasis X10 years without PsA compared with cases with PsA
PsX10 years without PsA (n=334) PsA (n=181) P-value
Male/female, N (%) 179 (53.6%)/155 (46.4%) 80 (44.4%)/100(55.6%) 0.048
Mean age of onset of Ps (years) 22.7±14.4 25.9±14.3 NS
Mean age of onset of PsA (years) NA 37.5±14.4 NA
Mean duration of PsA (years) NA 13.1±12.4 NA
Prevalence of smoking 32.1% 38.9% 0.12
NA, not applicable; Ps, psoriasis; PsA, psoriatic arthritis.
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were compared for each group with the non-psoriatic
controls (Table 3). This analysis revealed that the minor
allele of all three SNPs was significantly associated with
protection from PsA, which was most pronounced for
rs1800925 (OR 0.40, 95% confidence interval (CI)
0.25–0.65, Pallelic¼ 0.000067, Pgenotypic¼ 0.00014). Interest-
ingly, the allele frequencies in the Ps only group and PsZ10
years group are identical to that of controls. To confirm this,
we performed the same analysis in the GCI sample set
provided by Celera Corporation (Alameda, CA) in which the
necessary phenotypic data (number of years with Ps and
diagnosis of PsA) were available (Table 3). This analysis also
showed that the rs1800925*T was protective in the PsA group
of the GCI sample set (OR 0.53, 95% CI 0.33–0.83,
Pallelic¼ 0.0025, Pgenotypic¼ 0.008).
Effect of smoking and rs1800925 alleles on risk of PsA
As noted in previous studies, smoking appears to alter the risk
and severity of COPD depending on which alleles of IL13 are
present. We hypothesized that smoking could modulate the
protection from PsA in patients carrying rs1800925*T. For
this analysis, the prevalence of PsA was determined in four
groups: non-smokers with genotype CT or TT, smokers with
CT or TT, non-smokers with CC, and smokers with CC
(Table 4). The prevalence of PsA in non-smokers with CT or
TT was 13%, compared with 38% in smokers with CT or TT.
In contrast, the prevalence of PsA in non-smokers with the CC
genotype was 42%, and it was 47% in smokers with CC. We
conclude that smoking appears to abrogate the protective
effect of rs1800925*T, such that the prevalence of PsA among
patients who smoke with the rs1800925*T is comparable
Table 2. Clinical features of psoriasis cases with
genotype rs1800925 CC versus CT/TT
rs1800925 CC (n=337) CT/TT (123) P-value
Male/female (%) 49/51 52/48 0.56
Mean age of onset of Ps 28.5±16.3 29.2±18.1 0.71
PsA 108 (32.1%) 19 (15.5%) 0.0002
Mean age onset of PsA 38.6±14.6 35.0±13.9 0.32
Smokers 128 (38.1%) 48 (39.0%) 0.86
Ps, psoriasis; PsA, psoriatic arthritis.
Table 3. Association of IL13 polymorphisms rs1800925, rs20541, and rs848 with PsA and psoriasis without PsA
compared with controls in the Utah sample set
Marker Status Genotype OR (95% CI)1 PAllelic
2 PGenotypic
3
rs1800295 CC CT TT
UPI sample PsA (127) 108 (0.85) 17 (0.13) 2 (0.02) 0.40 (0.25, 0.65) 0.000067 0.00014
Ps (283)4 193 (0.68) 82 (0.29) 8 (0.03) 1.07 (0.81,1.41) 0.68 0.88
PsX10 years (208) 141 (0.67) 61 (0.29) 6 (0.03) 0.95 (0.70, 1.29) 0.76 0.94
Control (456) 303 (0.66) 139 (0.30) 14 (0.03)
Rs1800295 CC CT TT
GCI sample PsA (98) 76 (0.78) 21 (0.21) 1 (0.01) 0.53 (0.33, 0.83) 0.0025 0.008
Ps (396)4 259 (0.65) 129 (0.33) 8 (0.02) 0.89 (0.70, 1.12) 0.83 0.92
PsX10 years (143) 94 (0.66) 46 (0.32) 3 (0.02) 0.88 (0.63, 1.23) 0.25 0.23
Control (495) 316 (0.64) 158 (0.32) 21 (0.04)
Rs20541 GG GA AA
UPI sample PsA (181) 135 (0.75) 42 (0.23) 4 (0.02) 0.66 (0.47, 0.92) 0.015 0.051
Ps (447)4 294 (0.66) 142 (0.32) 11 (0.02) 1.09 (0.86, 1.38) 0.51 0.28
PsX10 years (334) 220 (0.66) 105 (0.31) 9 (0.03) 0.92 (0.72, 1.19) 0.56 0.46
Control (458) 298 (0.65) 140 (0.31) 20 (0.04)
Rs848 CC CA AA
UPI sample PsA (178) 132 (0.74) 42 (0.24) 4 (0.02) 0.65 (0.47, 0.92) 0.015 0.047
Ps (437)4 285 (0.65) 141 (0.32) 11 (0.03) 1.09 (0.86, 1.38) 0.51 0.40
PsX10 years (329) 216 (0.66) 104 (0.32) 9 (0.03) 0.91 (0.71, 1.18) 0.52 0.56
Control (458) 294 (0.64) 145 (0.32) 19 (0.04)
CI, confidence interval; GCI, Genomics Collaborative Division of SeraCare Life Sciences; OR, odds ratio; Ps, psoriasis; PsA, psoriatic arthritis; UPI, Utah
Psoriasis Initiative.
1All statistics compare sample set to control.
2Allelic P-values were performed using Fisher’s exact test.
3Genotypic P-values were performed using William’s corrected log-likelihood ratio tests. P-values are two-tailed, except for the GCI sample, for which
P-values are one-tailed as the hypothesis for this analysis was defined by the direction of the allelic effect in the Utah samples.
4Ps sample set includes the ‘‘PsX10 years’’ sample set.
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with the prevalence of PsA in non-smoking patients with the
common risk allele (CT/TT/non-smoker, prevalence of PsA
13%, OR 0.20, P¼0.0001; CT/TT/smoker, prevalence 38%,
OR 0.88, P¼0.74, CC/non-smoker, prevalence 42% (refer-
ence), CC/smoker prevalence 47%, OR 1.21, P¼ 0.47).
Effect of smoking on onset of PsA
Previously, we reported that smoking appeared to prolong the
time to development of PsA in the Utah sample set (Rakkhit
et al., 2007). To determine whether smoking and rs1800925
influence the time to development of PsA, we performed an
interaction analysis using one-way analysis of variance
(Table 5). Time from the development of Ps to PsA was
determined in smokers and non-smokers with or without
rs1800925*T. The analysis showed that smoking was
associated with delayed onset of PsA: non-smokers with
genotype CT or TT developed PsA 8.83±12.43 years after the
onset of Ps, compared with 17.57±14.49 years for smokers;
similarly, non-smokers with genotype CC developed PsA
12.43 years ±11.28 after the onset of Ps, compared with
16.37±13.10 years in smokers (P¼0.013). Interaction of
smoking and rs1800925 for delaying onset of PsA, however,
did not reach statistical significance (P¼0.08).
DISCUSSION
These results show that the minor alleles of three IL13
polymorphisms, rs1800925*T, rs20541*A, and rs848*A,
associate with protection from PsA in patients with Ps.
Previously, our group has reported association of Ps from four
polymorphisms within the IL13/IL4 region: rs1800925*T,
rs20541*A, rs848*A, and the SLC22A4 intronic SNP
rs11568506. We initially reported that the risk haplotype
(CCG) of rs1800925, rs20541, and rs848 conferred risk with a
combined OR of 1.27 (Pcombined¼ 1.88104) (Chang et al.,
2008). The follow-up study (Li et al., 2008) examined 106
polymorphisms in the IL13/IL4 region and concluded that
rs1800925 could account for observed significant association
of all but one other SNP, rs11568506 in SLC22A4, which
alone conferred only modest risk. However, these studies
only compared cases with Ps with non-psoriatic controls. Our
data suggest that the association of the IL13 SNPs with Ps
appears to be driven by the association with PsA. This
conclusion is based on data that show that the allele
frequencies in the groups where PsA cases were removed
are nearly identical to that of controls.
Two other large-scale genome-wide studies of Ps, which
included PsA sample sets in the analysis, have recently been
published. The Genetics Association Information Network
study, a genome-wide association of 1409 cases and 1436
controls that included the Utah sample set from this study,
also reported the association of rs20541 with Ps. The
replication phase of this study supported the association of
rs20541 with Ps and PsA, but a comparison of allele
frequencies for rs20541 between PsA cases and cutaneous
Ps only was not significant (P¼0.11) (Nair et al., 2009). It is
noted that this study did not include rs1800925, which is in
moderate linkage disequilibrium with rs20541 (r2¼0.24).
The genome-wide study reported by Liu et al. (2008), which
used a relatively small discovery set of 223 cases, including
91 PsA patients, also did not find association of Ps or PsA with
SNPs in the 5q31 region. Certainly, the size of the study
populations, differences in genetic architecture across popu-
lations, different environmental influences, and the modest
contribution of the IL13 polymorphisms may have contrib-
uted to the lack of power to find association of IL13 SNPs
with PsA in these studies. Further replication of our
association of PsA with rs1800925 is needed to confirm this
finding.
The biological role of IL13 polymorphisms and IL-13 in the
development of Ps or PsA remains unclear. No identified
functional role exists for rs1800925, which lies near the 50
end of IL13. This SNP, along with rs11568506, marks a risk
haplotype, and it is possible that an unidentified or untested
variant along this haplotype may be the true risk variant.
However, IL13 remains an interesting inflammatory disease
candidate, given the role that IL-13 has in the Th2-mediated
allergic inflammatory response seen in asthma, allergy,
helminthic responses, and atopic dermatitis (Lee et al.,
2007). IL-13 has not been detected in psoriatic skin, but
increased synovial IL-13 levels have been reported in patients
with PsA and rheumatoid arthritis (Spadaro et al., 2002).
Several in vivo and animal studies have suggested that IL-13
has protective effects related to inflammatory arthropathy,
including the following: (1) inhibition of tumor necrosis
factor-a activation of osteoclasts, (2) inhibition of cartilage
Table 4. Prevalence of PsA in smokers and
nonsmokers with CC versus CT/TT genotypes
rs1800925 Smoking PsA OR (95% CI) P-value1
CT/TT  7/55 (13%) 0.20 (0.08–0.48) 0.0001
CT/TT + 12/31 (38%) 0.88 (0.39–1.93) 0.74
CC  67/160 (42%) Reference Reference
CC + 41/88 (47%) 1.21 (072–2.05) 0.47
CI, confidence interval; OR, odds ratio; Ps, psoriasis; PsA, psoriatic
arthritis.
1Standard one-way analysis of variance was performed for comparisons
among the groups defined by smoking status and genotype.
Table 5. Mean time to development of PsA in smokers
and non-smokers with rs1800925 CC versus CT/TT
genotypes
Rs1800925 Smoking1
Mean no. of years from Ps
onset to PsA onset1
CT/TT  8.83±12.43
CT/TT + 17.57±14.49
CC  12.43±11.28
CC + 16.37±13.10
Ps, psoriasis; PsA, psoriatic arthritis.
1The interaction of genotype and smoking on mean number of years from
Ps onset to PsA onset was performed using one-way analysis of variance.
Smoking was associated with the delayed onset of PsA (P=0.013). The
interaction of smoking and the rs1800925 polymorphism had borderline
significance (P=0.08).
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destruction by downregulating activity of matrix metallopro-
teinases and blocking apoptosis of chondrocytes, (3) inhibi-
tion of angiogenesis thereby preventing overgrowth of
tortuous blood vessels within the synovium and (4) inhibition
of the production of inflammatory cytokines by monocytes
obtained from peripheral blood (Woods et al., 2002;
Palmqvist et al., 2006; Haas et al., 2007). Although these
findings do not clarify the role of elevated levels of IL-13 in
PsA, it is possible that IL-13 in the synovium counteracts the
Th1-mediated inflammatory milieu in PsA.
There is also increasing evidence that a correlation exists
between IL13 genotype, IL-13 expression, and smoking in a
variety of disease states. Our study is the first to suggest that
protection from PsA conferred by rs1800925*T could be
negated by a current or past smoking history. This protective
effect of the minor alleles of IL13 polymorphisms, which
included rs1800925, has also been shown in children who
were exposed to tobacco smoke in utero; children carrying
the minor alleles have less severe wheezing than those who
carried the common haplotype. However, in smokers who
develop COPD, it appears that it is the common allele rather
than the minor allele that protects from more severe airflow
obstruction.
The results of this study also show that smoking is
associated with delaying the onset of PsA in patients with
Ps. This finding has interesting parallels to inflammatory
bowel disease, which similar to Ps is influenced by smoking
and common genetic variants. In Crohn’s disease, tobacco
use is associated with later onset of disease and a more severe
course; in contrast, in ulcerative colitis, smoking is associated
with a less severe clinical course and decreased need for
corticosteroids and colectomy (Calkins, 1989; Mokbel et al.,
1998; Mahid et al., 2006, 2007). Crohn’s disease is also
associated with polymorphisms in the IL13/IL4 region (though
distinct from the Ps risk polymorphisms) (Wellcome Trust
Case Control Consortium, 2007; Li et al., 2008) and the same
polymorphism in IL23R that associates with Ps (Duerr et al.,
2006; Cargill et al., 2007). It is clear that further studies are
needed to determine the relationship between susceptibility
genes such as IL13 and smoking in immune-mediated
disorders and overlapping genetic and environmental triggers
such as Ps and inflammatory bowel disease.
Previous studies have examined the effect of smoking on
the development of inflammatory joint disease. Meta-analysis
of epidemiologic studies has suggested that smoking may
increase the risk for development of rheumatoid factor positive
rheumatoid arthritis (Sugiyama et al., 2009). The effect of
smoking on the development of rheumatoid factor positive
rheumatoid arthritis is influenced by gender, having a more
profound effect in males than females. In addition, Padyukov
et al. (2004) showed a gene–environment interaction for
rheumatoid factor positive rheumatoid arthritis. In this study,
the risk gene, a shared HLA-DRB1 epitope, conferred even
greater risk in current smokers compared with non-smokers
(relative risk¼ 2.8 (95% CI 1.6–4.8) for non-smokers versus
relative risk¼15.7 (95% CI 7.2–34.2) for current smokers).
There are several limitations to our study that must be
considered when interpreting the results. First, the diagnosis
of PsA in all participants was self-reported as having been
diagnosed by a rheumatologist. We did not have a
rheumatologist independently confirm the diagnosis; how-
ever, all patients were seen by dermatologists trained in
assessing PsA, and equivocal cases were excluded from the
study. In addition, no data were collected on disease severity,
joints affected, or subclassification of PsA. Our ‘‘Ps only’’
subsets may also have included patients who have undiag-
nosed PsA or will go on to develop it. We chose to limit this
possibility by creating a set of psoriasis cases who have had
Ps for at least 10 years without PsA, as it is reported that most
patients who will develop PsA do so within the first 10 years
(Gladman et al., 2005). The diagnosis, or lack of diagnosis of
PsA, could also have been confounded by treatment history,
which we did not take into account. Systemic therapies such
as methotrexate or biological agents could have masked
clinical signs or symptoms of PsA, thus decreasing the
likelihood of detecting PsA, or even reducing the likelihood
of developing PsA despite a genetic or environmental
predisposition. Yet another limitation of the study was that
smoking history was not quantified in a detailed manner,
which prevented our ability to identify a dose-dependent
relationship of smoking to PsA. Evaluation of additional
sample sets in an attempt to replicate these results is
imperative for strong conclusions to be drawn. Prospectively
enrolled databases of patients with psoriatic disease with
detailed clinical information, including rheumatologic ex-
amination and detailed smoking history, are needed to
confirm these data.
In summary, our data suggest that polymorphisms in the
IL13/IL4 region, a previously identified autoimmune suscept-
ibility locus, may associate with PsA more than Ps with
cutaneous manifestations alone, and this susceptibility may
be influenced by smoking history. This study supports the
hypothesis that genes and environment may interact to
influence the development of PsA. Further studies are needed
to confirm our findings and to elucidate the biological
pathways influenced by IL13 and tobacco use.
MATERIALS AND METHODS
Utah participants
Detailed demographic and clinical data as well as genotype data
were obtained from participants with Ps enrolled in the Utah Ps
Initiative. This study was approved by the University of Utah
Institutional Review Board and conducted according to the
Declaration of Helsinki principles. All participants provided written
informed consent and had been recruited from dermatology clinics
affiliated with the University of Utah. Enrollment included comple-
tion of a questionnaire, detailed physical examination, an interview
by a trained research physician, and collection of a peripheral blood
sample for DNA extraction.
All eligible participants from the Utah Psoriasis Initiative were
examined and confirmed to have Ps. Patients were considered to have
PsA if the patient reported that a rheumatologist had diagnosed PsA.
Equivocal cases of PsA were excluded from the analysis. Smoking
history was obtained by patient self-report on the intake question-
naires. Patients were considered smokers if they answered ‘‘yes’’ to the
question,‘‘ have you ever smoked cigarettes on a routine basis?’’
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The replication study population was collected by the Genomics
Collaborative Division of SeraCare Life Sciences (GCI) as described
elsewhere (Cargill et al., 2007). The patients in this study set had
dermatologist-confirmed Ps. Presence of PsA, age of onset of Ps, and
age of onset of PsA had also been dermatologist-reported.
For the association analysis, the Ps sample sets were divided into
three groups: cases with Ps and PsA (‘‘PsA’’), cases with Ps without
PsA regardless of duration of Ps (‘‘Ps’’), and cases with Ps for Z10
years without PsA (‘‘PsX10 years’’). The 10-year cutoff was
arbitrarily chosen to create a set of patients who were less likely to
develop PsA, given that most patients develop PsA within the first 10
years of developing Ps (Gladman et al., 2005).
Genotyping
All genotyping was performed at Celera Corporation. Genotyping
methodology and the association of Ps with the three IL13
polymorphisms, rs1800925 (50 promoter), rs20541 (exon 4), and
rs848 (30UTR) in the 467 Utah patients and 460 controls and GCI
replication sample set (495 cases, 495 controls) are described in our
previous publications (Cargill et al., 2007; Chang et al., 2008). An
additional 233 patients from the Utah Psoriasis Initiative were also
genotyped for rs20541and rs848 as part of the replication effort of
the Genetics Association Information Network genome-wide asso-
ciation study of Ps (Nair et al., 2009).
Statistical analysis
Allelic OR and 95% CI were calculated by comparison of the total
number of each allele found among cases and controls. P-value
testing for differences in allele frequencies and genotype frequencies
were calculated using Fisher’s exact test (for allelic P-values) and
William’s corrected log-likelihood ratio test. T-tests were used
to compare the means of quantitative variables between cases
and controls and standard one-way analysis of variance was
performed for comparisons among multiple groups defined by
smoking status and genotype. One-way analysis of variance was
used to determine the effect of the interaction of smoking and
genotype on the delay of onset of PsA. All significance tests were
two-sided, with the exception of the association analysis in the
replication group, which was one-sided as the hypothesis for this
analysis was defined by the direction of the allelic effect in the Utah
samples. Statistical analyses were performed using STATA 9.0 (Stata
Corp., College Station, TX).
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